With advances in immunotherapy in ES-SCLC, the treatment mode of addition other drug (“X” represent other drug) to PD-1(L1) inhibitor plus chemotherapy has emerged as an important research direction. This evidence concerns the gene PDCD1 and small cell lung carcinoma.